Susoctocog alfa
From Wikipedia, the free encyclopedia
Susoctocog alfa, sold under the brand name Obizur, is a medication used for the treatment of bleeding episodes in adults with acquired haemophilia, a bleeding disorder caused by the spontaneous development of antibodies that inactivate factor VIII.[6][5][7]
Quick Facts Clinical data, Trade names ...
Clinical data | |
---|---|
Trade names | Obizur |
Other names | Antihemophilic factor (recombinant) |
AHFS/Drugs.com | Monograph |
License data | |
Pregnancy category |
|
Drug class | Antihemophilic factor |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
DrugBank | |
UNII | |
KEGG |
Close
Susoctocog alfa was approved for medical use in the United States in October 2014,[8][9] and for medical use in the European Union in November 2015.[6]
Factor VIII is one of the proteins needed for normal clotting of the blood.[6]